Acceleration

FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA

Retrieved on: 
Thursday, April 4, 2024
Diabetes, Fibroblast, EGFR, Warfarin necrosis, Risk, Communication, IL-6, Form, Diabetic foot ulcer, Conditional sentence, Patient, Research, Mouse, Gamma ray, Trial of the century, HDF, Hyperglycemia, Acceleration, Wound healing, Cytokine, Therapy, Cellular senescence, Interleukin, VEGF, Pharmaceutical industry

These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.

Key Points: 
  • These findings will be presented via an oral and poster presentation at the Advanced Wound Care Summit USA in Boston, MA, April 16-17.
  • Diabetic foot ulcers (DFUs) are prevalent in individuals with diabetes, with approximately 33 million people impacted globally.
  • FibroBiologics' research aims to address this issue by investigating the potential of using human dermal fibroblast (HDF) spheroids in promoting and accelerating the wound healing process in diabetic patients.
  • "These results support the potential of HDF spheroids to expedite the healing process of chronic wounds associated with diabetes," said Dr. Khoja.

What to Expect at Qlik Connect 2024: Qlik Announces 100+ Breakout Sessions, Amazon AWS Returns as a Diamond Sponsor

Retrieved on: 
Thursday, April 4, 2024
Diamond, Research, Synthetic media, Organization, Acceleration, Chatbot, Artificial intelligence, AI, Life, Building, AWS, Amazon Web Services, Competition, Generative

Qlik Connect will take place on June 3-5 at the Rosen Shingle Creek in Orlando, Florida.

Key Points: 
  • Qlik Connect will take place on June 3-5 at the Rosen Shingle Creek in Orlando, Florida.
  • It's this community and exchange of ideas that truly amplify the value we get from Qlik."
  • This year’s breakout sessions will offer attendees an opportunity to participate in inspiring discussions spanning all things data, analytics and AI.
  • Click here to view a full list of Qlik and Talend certifications, and to reserve your spot to get verified.

Amplitude, Inc. Class Action: Levi & Korsinsky Reminds Amplitude Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 15, 2024 – AMPL

Retrieved on: 
Thursday, April 4, 2024
Acceleration, Telephone, COVID-19, LLP, CLASS, NEXT, COST, Court, Cryptocurrency

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amplitude, Inc. ("Amplitude" or the "Company") (NASDAQ: AMPL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Amplitude, Inc. ("Amplitude" or the "Company") (NASDAQ: AMPL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Amplitude investors who were adversely affected by alleged securities fraud between September 21, 2021 and February 16, 2022.
  • Follow the link below to get more information and be contacted by a member of our team:
    AMPL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Investigation into Avid Bioservices, Inc. Underway: Johnson Fistel, LLP Digs into Alleged Securities Law Violations - What Shareholders Need to Know!

Retrieved on: 
Wednesday, April 3, 2024
Failure, CDMO, Acceleration, SAN, LLP, Security (finance), Note, Investment, Debt-to-GDP ratio

SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities laws by Avid Bioservices, Inc. (NASDAQ: CDMO) ("Avid" or "the Company").

Key Points: 
  • SAN DIEGO, April 03, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of securities laws by Avid Bioservices, Inc. (NASDAQ: CDMO) ("Avid" or "the Company").
  • We are looking into whether the Company or its executives failed to disclose vital information to investors, leading to losses on their investments.
  • If you have purchased Avid securities and have experienced losses, we encourage you to join our investigation to potentially make claims and recover under federal securities laws.
  • What if I purchased Avid securities?

Sekur Private Data to Harness AI to Turbocharge Enterprise Sales Strategy

Retrieved on: 
Wednesday, April 3, 2024
Automation, Consultant, Government, Acceleration, Partnership, FRA, AI, Workforce, Privacy, OTCQB, Marketing, FINRA, Sales

MIAMI, FL and TORONTO, ON, April 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Sekur Private Data Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA:GDT0) (“Sekur” or the “Company”), a leading Swiss hosted secure and private communications platform, announced the launch of an advanced marketing initiative leveraging artificial intelligence (AI) and automation to accelerate its enterprise sales strategy and fuel revenue growth.

Key Points: 
  • MIAMI, FL and TORONTO, ON, April 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Sekur Private Data Ltd. (OTCQB:SWISF) (CSE:SKUR) (FRA:GDT0) (“Sekur” or the “Company”), a leading Swiss hosted secure and private communications platform, announced the launch of an advanced marketing initiative leveraging artificial intelligence (AI) and automation to accelerate its enterprise sales strategy and fuel revenue growth.
  • This data-driven approach will enable highly targeted marketing campaigns, personalized messaging, and optimized sales strategies tailored for enterprise cybersecurity decision makers.
  • These partners will offer Sekur 's Swiss-hosted privacy communications solutions as a value-add to complement their existing enterprise offerings.
  • For sales brochure on our enterprise security solutions, or partnership opportunities, contact [email protected]
    To find out more about Sekur’s privacy communications solutions visit: https://sekur.com/

DEADLINE ALERT for INMD, AMPL, NOVA, DKS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, April 3, 2024
Law, Acceleration, Risk, Telephone, COVID-19, Class, Outdoor, Suite, Investment, Amplitude, FDA

BENSALEM, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2024 in Amplitude Lawsuit – AMPL

Retrieved on: 
Wednesday, April 3, 2024
NEXT, AMPL, COVID-19, Fraud, Acceleration, Security (finance)

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. (NASDAQ: AMPL).

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Amplitude, Inc. (NASDAQ: AMPL).
  • Shareholders who purchased shares of AMPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • DEADLINE: April 15, 2024 Shareholders should not delay in registering for this class action.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

INVESTOR ALERT: Amplitude, Inc. (NASDAQ: AMPL) Investors With Losses of More Than $100,00 Encouraged to Seek Appointment as Lead Plaintiff – April 15, 2024 Deadline

Retrieved on: 
Wednesday, April 3, 2024
District court, COVID-19, SAN, Acceleration, News, Cryptocurrency

This action is pending in the United States District Court for Northern District of California.

Key Points: 
  • This action is pending in the United States District Court for Northern District of California.
  • Until a class is certified, you are not represented by counsel unless you retain one.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
  • On this news Amplitude stock decline $24.51 per share to close at $17.10 on February 17, 2022.

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amplitude

Retrieved on: 
Wednesday, April 3, 2024
Acceleration, COVID-19, News, LLP, Advertising, Court, Cryptocurrency

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amplitude’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings

Retrieved on: 
Wednesday, April 3, 2024
Clobetasol, Exchange, Infection, Acceleration, Refractive surgery, Inflammation, Annual general meeting, ASCRS, Patient, Private practice, Cataract, Society, Ophthalmology

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today announced that the company will be conducting demonstrations of its portfolio of commercial products at two upcoming ophthalmology medical meetings.

Key Points: 
  • “Our presence at national medical and commercial meetings like these are key to elevating awareness of our continuum of office-based and surgical products,” stated Michael Rowe, Eyenovia’s Chief Executive Officer.
  • These meetings complement the efforts of our field sales force in amplifying the synergistic nature of our product portfolio as well as the many benefits conferred to doctors and patients by the Optejet device.
  • Eyenovia will also be demonstrating Avenova and reviewing now-approved data on clobetasol, which complements the company’s surgical suite of products.
  • The event features continuing education, keynote speakers, Exchange-only pricing from more than 100 vendors, and opportunities to network with colleagues.